FDA Approves Neratinib for HER2-Positive Breast Cancer

The FDA has approved neratinib (Nerlynx) for use as extended adjuvant treatment in adult patients with early-stage HER2-positive breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news